Sep. 15 at 2:32 AM
$SLS I wonder how many of the Inch Thick Mile Wide Retail Lemmings Know Final SLS009 Phase 2 Data for AML-MR Patients Published at ASH -- is better than the Magrolimab P1B AML-MR data published at ASH that
$GILD bought for
$4.9B
- Just the Secondary Asset SLS009 / Tambiciclib, completed a 87 Patient Phase 1 trial in 7 Hematological Cancers, and Completed a Phase 2 Trial that achieved better survival (4x Os over Soc) and safety data than a drug that got bought for
$4.9B by
$GILD, and
AND --- AND is Now in an
• Phase 2 AMLMR Expansion Trial at the Request of FDA:
• 80 patients
• dual arm
• Randomized and
• Pivotal
• with FDA Greenlight Data incoming next quarter – in Q4
• list FDA approved drugs based on Ph1/2 data like the trial 009 is now in.
